1IA
NVO

1620 Investment Advisors’s Novo Nordisk NVO Stock Holding History

1620 Investment Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.6K Hold
96
– – ﹤0.01% 559
2026
Q1 		$3.53K Hold
96
– – ﹤0.01% 546
2025
Q4 		$4.88K Hold
96
– – ﹤0.01% 520
2025
Q3 		$5.33K Hold
96
– – ﹤0.01% 512
2025
Q2 		$6.63K Sell
96
-75
-44% -$5.1K ﹤0.01% 503
2025
Q1 		$11.9K Buy
171
+40
+31% +$3.3K 0.01% 427
2024
Q4 		$11.3K Sell
131
-45
-26% -$4.87K 0.01% 441
2024
Q3 		$21K Hold
176
– – 0.02% 391
2024
Q2 		$25.1K Buy
+176
New +$23.3K 0.02% 368

Other funds holding NVO

SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
GIM
Generate Investment Management Auckland, New Zealand $2.43B AUM 37.24% 1-Year Est. Return
CFB
Cullen/Frost Bankers San Antonio, Texas $10.1B AUM 29.18% 1-Year Est. Return
OFA
Oak Family Advisors Chicago, Illinois $391M AUM 26.35% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

1620 Investment Advisors's NVO Position: Q2 2026 in Review

1620 Investment Advisors held its Novo Nordisk (NVO) position steady in Q2 2026 at 96 shares worth $4.6K. The position accounts for ﹤0.01% of the portfolio, ranked #559.

1620 Investment Advisors first reported a position in NVO in Q2 2024 and has held it in 9 quarters since. The position peaked at $25.1K in Q2 2024. 479 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • 1620 Investment Advisors held 96 shares of Novo Nordisk worth $4.6K as of Q2 2026.
  • 1620 Investment Advisors left its Novo Nordisk share count unchanged in Q2 2026.
  • Novo Nordisk made up ﹤0.01% of 1620 Investment Advisors's portfolio in Q2 2026, its #559 holding.
  • 1620 Investment Advisors first reported a position in Novo Nordisk in Q2 2024 and has held it in 9 quarters since.
  • 1620 Investment Advisors's Novo Nordisk position peaked at $25.1K in Q2 2024.
  • 479 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on 1620 Investment Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.